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Summary Vascular infections typically include those of surgical sites, prosthetic grafts,
and vascular ulcers, including some diabetic foot ulcers. Each of these infections represents
a serious health concern, particularly among individuals with comorbid conditions who are
at an increased risk of morbidity and mortality. Surgical site infections occur primarily
as a result of contamination by skin organisms during surgery, whereas prosthetic graft
infections result typically from a progressive wound infection. Diabetic foot ulcers and
infections are especially complicated and difﬁcult to treat. They occur in individuals with
systemic illness that has compromising effects on the nervous, vascular, musculoskeletal,
and immunologic systems. Vascular infections, like those elsewhere in the body, reﬂect
an imbalance between the host and bacteria. Efforts to limit or prevent the likelihood of
patients developing these infections centre on reducing the bacterial inoculum by means
of asepsis and antisepsis. As well as size of the bacterial inoculum, the bacterial properties
of pathogenicity and resulting virulence are also signiﬁcant. The most frequent pathogenic
bacteria encountered in surgical patients are Gram-positive cocci (e.g. Staphylococcus
aureus and streptococci). Strains with multiple antibiotic resistance (e.g. meticillin-
resistant S. aureus [MRSA], S. epidermidis, and vancomycin-resistant enterococci [VRE])
can cause signiﬁcant surgical site infection problems. Local resistance patterns and
surveillance efforts are essential to ensure appropriate empiric antibiotic selection for
prophylaxis or treatment.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
Introduction
Despite the advent of antimicrobial therapy, infectious
diseases continue to emerge and reemerge as antimicrobial
resistance among bacteria increases. A study by Pinner
et al. 1 showed the alarming trend that, between 1980
and 1992, mortality in the USA as a result of infectious
diseases increased by 58%. This study further showed
that age-adjusted mortality increased by 39% and that
mortality in men exceeded that in women by almost
ﬁve times 1. Although vascular infections are relatively
infrequent, they are associated with high morbidity and
mortality 2. For example, prosthetic graft infections can
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be both limb- and life-threatening 2. Co-morbid conditions
that increase the risk of vascular infection include,
but are not limited to, diabetes, ischaemic leg ulcers,
and smoking 2. Treatment of these infections and those
caused by bioﬁlm-producing bacteria represent a signiﬁcant
clinical challenge. Antibiotic therapy has decreased the
mortality associated with vascular infections; however, a
successful therapeutic outcome depends on not only the
location and extent of the infection, but also the type of
organism and its sensitivity to the selected antibiotics 2.
Antimicrobial resistance among bacteria is an increasing
threat. Clinically important drug-resistant bacteria that
commonly cause healthcare-associated infections include
meticillin-resistant Staphylococcus aureus (MRSA) and
meticillin-resistant coagulase-negative staphylococci (CNS,
eg S. epidermidis and others); vancomycin-resistant
enterococci (VRE), and multidrug-resistant Gram-negative
rods, including strains of Pseudomonas aeruginosa,
1201-9712/$30.00 © 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Table 1
Surgery- and patient-related risk factors for surgical site infection
Surgery-related risk factors Patient-related risk factors
Delayed surgery Advanced age
Long surgical procedure Chronic renal insufﬁciency
Presence of a groin incision Diabetes mellitus
Postoperative seroma, lymphocele, or haematoma Distal skin necrosis or gangrene
‘Re-do’ surgery Female gender
Undermining skin edges Malnutrition
Use of prosthetic graft material Obesity
Preoperative use of aspirin
Rest pain
Stenotrophomonas maltophilia, and Acinetobacter spp.
which may be resistant to most available antimicrobials.
CNS, Enterococcus spp., P. aeruginosa and S. aureus have
all been isolated from bioﬁlms on prosthetic valves and
central venous catheters 3. In addition, strains of S. aureus
and CNS with reduced susceptibility to vancomycin
and other glycopeptide antibiotics have recently been
reported 4,5. Vancomycin resistance among enterococci
is of particular importance, as among intensive care
unit patients with nosocomial infections, the percentage
of enterococcal isolates resistant to vancomycin has
increased from 0.5% in 1989 to 25.2% in 1999 6,7.
Recognition of the risk factors that precipitate these
infections, minimisation of those risk factors, together
with early recognition and prompt treatment of the
infections, are essential. Here, we discuss the three
most commonly encountered vascular infections: those
of surgical sites, prosthetic grafts, and diabetic foot
infections, with an emphasis on empiric antimicrobial
options for the prevention or treatment of such infections
in an era of ever increasing antimicrobial resistance.
Surgical site infections
It is estimated that more than 27 million surgical
procedures are performed annually in the USA, and as the
population ages, this number is likely to increase 8. Despite
reﬁned surgical techniques, environmental changes in the
operating room, and the use of preventive antibiotics,
infection at the surgical site continues to be a major
source of morbidity following operative procedures 9. In
addition, surgical site infection prolongs hospitalisation
and increases many other costs that could have been
avoided if infection had not occurred 9. Surgical site
infections are the most commonly encountered nosocomial
infections in surgical patients. They occur in up to 20% of
all patients who are admitted to the hospital for skin and
soft tissue infection 10. There are a number of predisposing
factors that put these patients at a higher risk for surgical
site infections, including diabetes, smoking, obesity, and
malnutrition 11. Table 1 shows the common surgery- and
patient-related risk factors for surgical site infection
following surgery.
The Centers for Disease Control and Prevention (CDC)
and the National Nosocomial Infections Surveillance (NNIS)
group undertook a formal, logistic regression analysis in
which they evaluated all of the potential risk factors for
surgical site infection. They found three factors that were
strongly linked with incidence of surgical site infection: an
American Society of Anesthesiology score of greater than
or equal to 2; having a contaminated or dirty wound; length
of operation time being greater than the 75th percentile
for the operation being performed 12. In addition, a new
factor has emerged: being colonised with S. aureus prior
to surgery. Colonisation with this organism has been shown
to have a signiﬁcant association with MRSA surgical site
infection 11.
In 1999, the CDC published guidelines designed to
help prevent surgical site infections 11. These guidelines
highlight the need for antimicrobial prophylaxis, operating
room ventilation, normothermia, and glucose control as
standard prophylactic strategies. Whether supplemental
oxygen should be given perioperatively remains controver-
sial. A study published in 2000 saw a 50% reduction in
surgical site infections in patients undergoing colorectal
cancer surgery if they were given 80% oxygen compared to
patients given 30% oxygen during, and for 2 hours after,
surgery 13. This study prompted many hospitals to adopt
this approach as the standard of care. In 2004, however,
the study was reproduced in a general surgical patient
population, and although the study design was the same,
these investigators saw no difference in the incidence of
surgical site infection 14.
It is clear that the mainstay of surgical site infection
prophylaxis is antimicrobial prophylaxis. Numerous studies
have demonstrated reductions in the rate of surgical
site infection in patients undergoing surgery when an
antibiotic was administered preoperatively 15-20. Stone
and coworkers 20 demonstrated that multiple doses given
preoperatively in biliary and gastrointestinal surgery are no
better than a single preoperative dose, and that antibiotics
initiated postoperatively have the same rate of surgical
site infection as placebo. In another study, the same
authors showed that a regimen of ﬁve postoperative days
of preventive antibiotics after preoperative administration
was no better than the perioperative administration
alone 19. From these and other studies, speciﬁc criteria
for the use of preventive antibiotics in surgery have
subsequently been developed 15. Prolongation of antibiotic
administration beyond the immediate perioperative period
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does not appear to improve results. In fact, prolonged
postoperative administration of preventive antibiotics
increases antibiotic-associated morbidity (e.g. Clostridium
difﬁcile enterocolitis), increases the resistance of nosoco-
mial bacteria 21, and increases costs 22.
The leading causes of surgical site infections are
S. aureus and streptococci. S. aureus is particularly
troubling as the vast majority of strains isolated in the
USA today have meticillin resistance. Data from the CDC
for 2004 indicate that, in the hospital setting, 59.5% of
all S. aureus infections are now meticillin-resistant 12.
Recent studies indicate that MRSA surgical site infection is
associated with higher mortality, greater length of stay, and
greater cost compared with meticillin-sensitive S. aureus
(MSSA) infection 23.
The rising rate of MRSA in the surgical patient population
provoked a change to the 1999 guidelines. In 2004, the
Surgical Infection Prevention Group published an updated
version of the guidelines that addresses MRSA surgical
site infection 24. One study in particular prompted this
change 25. The study looked at 885 cardiac surgical patients
who were randomised to either cefazolin or vancomycin.
While there was no difference in the rate of surgical site in-
fections, there was a difference in the microbiology. When
patients developed surgical site infections, those who
received cefazolin developed MRSA infections, whereas
the group that was treated with vancomycin developed
MSSA infections 25. Table 2 lists the antibiotics currently
approved for the treatment of MRSA infections. Clearly, ad-
ministration of an antibiotic with the appropriate spectrum
of activity is critical to preventing surgical site infection.
Table 2
Antimicrobial therapeutic options for the treatment of MRSA
infections
Agent Comment(s)
Oral agents
TMP/SMX Highly susceptible; not active vs
streptococci
Rifampin Rapid resistance when used alone
Clindamycin >90% susceptible
GI side effects
Inducible clindamycin resistance
Tetracyclines 85–90% susceptible
Linezolid Highly active
IV agents
Vancomycin “Gold standard” for MRSA
Clindamycin >90% susceptible
GI side effects
Inducible clindamycin resistance
Linezolid Highly active
Daptomycin Used for skin and soft tissue infections;
poor activity in pneumonia
Tigecycline Used for complicated skin and soft tissue
infections and intra-abdominal infections
Dalbavancin Once weekly dosing
Prosthetic graft infections
Infections developing in prosthetic vascular graft material
are generally rare events, occurring at rates between
0% and 3.1%. However, graft infections when they do occur
are a severe complication of vascular surgery and are
associated with signiﬁcant morbidity (systemic illness and
major limb amputation) and mortality 26-29.
Most graft infections occur in the groin 27, and, as with
other lower-extremity graft infections, usually occur in
the early postoperative period, typically as a result of a
progressive surgical site infection 29. Comorbid risk factors
associated with graft infections include the presence
of ischaemic leg ulcers, diabetes, smoking, infected
lymph nodes, and transient bacteraemia from a purulent
draining wound or sinus, an abscess, a lymphocele, skin
necrosis, pain, septic emboli with petechia, a pulsatile
mass, fever, or graft thrombosis 27,29-32. Surgery-related
factors that increase the risk of graft infection include
the type of graft material involved, graft construc-
tion, improperly sterilised materials, break in sterile
technique, implantation site, improper administration of
antibiotics, endogenous ﬂora, concomitantly performed
surgical procedure, emergency operations, reoperation
at the site of infection, and prolonged operating room
time 33. Antonios and colleagues 34 recently published the
ﬁrst risk-factor analysis that included statistical evaluation
in a case-controlled study of prosthetic vascular graft
infection, and found groin incision, wound complication,
and wound infection to be signiﬁcantly associated with the
development of vascular graft infection 34.
Historically, the most common pathogen found in early-
onset infections were coagulase-positive staphylococci,
such as S. aureus, and in late-onset infections coagulase-
negative staphylococci such as S. epidermidis were most
common. More recently, mixed pathogens have predom-
inated as causative organisms in these infections 27,29.
S. aureus and S. epidermidis, together with Escherichia
coli, currently make up 75% of early and late graft
infections 35. Proteus spp. and P. aeruginosa have also
been found 35. MRSA was reported to be the most common
organism isolated in vascular graft infections; Earnshaw 36
reported MRSA graft infections being associated with a
signiﬁcant increase in the risk of amputation and prolonged
duration of hospitality.
Despite the use of systemic antibiotic prophylaxis, vas-
cular graft infections still occur. To address this problem,
antibiotic- and antimicrobial-impregnated grafts have been
developed and used in experimental and clinical studies
to assess their preventative effectiveness. For example,
Giacometti and colleagues 37 have used a rat model
to show the effectiveness of quinupristin–dalfopristin-
soaked grafts, as well as grafts impregnated with the
peptides ranalexin and buforin II, in the prevention
of vascular prosthetic graft infections. Similarly, Yasim
and coworkers 38 found vancomycin-, teicoplanin- and
40% fusidic acid-soaked grafts to be effective in preventing
primary prosthetic vascular graft infection in rats, and
Lehnhardt et al. 39 also used an animal model to show
that local and systemic antibiotic prophylaxis improves
protection against graft infection. Another in vitro study 40
reported that daptomycin and linezolid exhibited more
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potent antimicrobial activity against device-adherent
staphylococci compared with gentamicin or vancomycin. In
clinical studies, rifampin-impregnated Dacron grafts have
been used for the prevention of vascular graft infection 38.
All types of prosthetic vascular grafts are susceptible in
varying degrees to infection via direct contamination dur-
ing implantation or bacteraemia after operation. Dacron
and ePTFE are the most frequently used materials. ePTFE
is relatively nonporous compared with Dacron and is more
hydrophobic than Dacron. This may explain why it is less
likely to form bonds with those bacteria whose cell walls
have hydrophobic properties. Turgut et al. 41 found that
S. epidermidis, S. aureus and E. coli have greater afﬁnity
to Dacron grafts when compared with ePTFE; they conclude
that this ﬁnding may be of clinical importance and might
inﬂuence the surgeon’s choice when selecting a graft.
The gold standard for treatment of an infected
prosthetic graft remains explantation of the graft and
subsequent reperfusion by placing a new graft, most
commonly via an extra-anatomic uninfected route 42 and
less commonly via in situ grafting using an autogenous
(vein) conduit. Antimicrobial therapy is a vital adjunct
to surgical management; in some cases it may be the
only option if the patient is not ﬁt for further operative
intervention.
The British Society for Antimicrobial Chemotherapy
(BSAC) Steering Group on the treatment of hospital
infections recommends treatment with cefuroxime and
metronidazole, with or without amoxicillin, as appropriate
empiric therapy for early-onset prosthetic vascular graft
infections 43. For penicillin-allergic patients, ciproﬂoxacin
and clindamycin are suggested as alternative agents.
Given that S. aureus is the most frequently isolated
organism in early infection, and that meticillin resistance
is increasingly common, it has been suggested that
empiric treatment of early-onset infection should include
a glycopeptide where MRSA is prevalent 44. For late-onset
infections, the BSAC guidelines recommend that antibiotic
treatment be deferred until the infective aetiology has
been conﬁrmed, except in the very ill patient. Accordingly,
there is little guidance as to the appropriate management
of a patient in whom graft infection is suspected, but
not conﬁrmed, but who cannot tolerate surgery to remove
the infected graft or to obtain appropriate specimens 45.
Indeed, it is not uncommon for a surgeon to be faced with
a patient whose ﬁtness for surgery is questionable due to
the presence of multiple risk factors unrelated to the graft.
Such patients are more likely to experience post-operative
problems in the long to medium term. A multi-disciplinary
group to provide expert consensus and guidance in the
management of such patients is warranted.
Diabetic foot infections
Diabetic foot infections can be non-limb-threatening
or limb-threatening 46. Non-limb-threatening infections
include superﬁcial infections without systemic toxicity,
minimal cellulitis extending less than 2 cm from the portal
of entry, and ulceration not extending fully through the
skin and lacking signiﬁcant ischaemia. Limb-threatening
infections include more extensive cellulitis, lymphangitis,
ulcers penetrating through skin into subcutaneous tissues,
and prominent ischaemia 46.
As with other vascular infections, S. aureus is the
most common pathogen isolated in non-limb-threatening
infections 47. Facultative streptococci are the second
most common cause of these infections. Limb-threatening
infections tend to be polymicrobial. Again, S. aureus
is a major pathogen, as are group B streptococci,
Enterococcus spp., and facultative Gram-negative bacilli.
Anaerobic Gram-positive cocci, Peptostreptococcus spp.
and Bacteroides spp. may also be present 47.
Antimicrobial treatment for a non-limb-threatening
infection is usually selected to address staphylococci
and streptococci 47. Mild infections can be treated at
home with oral clindamycin, cephalexin, amoxicillin/
clavulanate, or dicloxacillin. Superﬁcial diabetic ulcers
that are complicated by cellulitis generally require
parenteral antibiotics, such as intravenous cefazolin
or nafcillin 47. Initial antimicrobial treatment of limb-
threatening infections requires broad-spectrum antibiotics
because of the polymicrobial nature of these infections.
A variety of antibiotic regimens are advocated for initial
empiric therapy of diabetic foot infections 47,48. The combi-
nation of dindamycin and cefepime or a ﬂuoroquinolone has
often been used, as has cefoxitin or ampicillin/sulbactam.
Combination therapy with clindamycin and levoﬂoxacin
offers broad coverage and is also a common empiric
therapy for diabetic foot infections 47,48. Once culture and
sensitivity results are obtained, the initial antibiotic can
be modiﬁed as necessary.
If, despite adequate wound care and culture-directed
antibiotics, a non-healing infected diabetic foot ulcer
worsens, surgery is required to debride infected tissue
and achieve a healed wound to restore the functional
status of the limb. Stabilising the vascular and orthopaedic
components of diabetic foot ulcers is necessary to impede
the progression of the ulcer-infection–amputation scenario.
Diabetes is the leading cause of amputation in the USA. In
2002, 82,000 lower-extremity amputations were performed
on diabetic patients 49. For many patients, their diabetes is
complicated by comorbid conditions, particularly involving
kidneys and liver. The most common indications for
amputation are gangrene or infection in a non-healing
ulcer 50. Morbidity and mortality rates are high following
amputation. The National Institutes of Health reported that
the mortality rate 1 year after amputation is between
11% and 41%, the 3-year post-amputation mortality rate
is 20–50%, and the 5-year rate is 39–68% 51.
Summary
The optimal treatment for vascular infections is pre-
vention. When these infections do occur they become
potentially limb- and life-threatening complications.
Gram-positive aerobes are the organisms most frequently
identiﬁed in patients who develop vascular infections,
with S. aureus being the most common. MRSA has
emerged as a leading cause of postoperative infection in
vascular surgery patients. It is associated with substantial
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morbidity, increased length of hospital stay, and higher
incidences of amputation and graft removal. Greater
emphasis on preoperative screening protocols for MRSA
colonisation should be considered, as well as aggressive
infection control measures, alteration of preoperative
prophylactic antimicrobial use in MRSA-colonised patients,
and meticulous postoperative surveillance for MRSA
infection. Antimicrobial treatment should include empiric
coverage for MRSA in institutions where MRSA is endemic.
New antimicrobial options that could be considered include
linezolid, daptomycin, tigecycline, and the investigational
drug dalbavancin.
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